# To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus

> **NCT07447986** · PHASE2 · RECRUITING · sponsor: **Hangzhou Sumgen Biotech Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus (SLE)

## Interventions

- **DRUG:** SG301 SC Injection
- **DRUG:** SG301 SC Injection
- **DRUG:** SG301 SC placebo

## Key facts

- **NCT ID:** NCT07447986
- **Lead sponsor:** Hangzhou Sumgen Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-26
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07447986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07447986, "To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07447986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*